MEDBOT-B shares surge over 4% intraday; UOB Kay Hian initiates coverage with 'Buy'

Deep News08-11

MEDBOT-B (02252) saw its share price rise more than 4% during intraday trading. As of the time of writing, the stock was up 3.25%, trading at HKD 24.12, with a turnover of HKD 59.35 million.

Recently, MEDBOT-B issued a profit alert, forecasting a net profit of between RMB 28 million and RMB 40 million for the first half of the year. This compares to a loss of RMB 115 million in the same period last year, marking the company's first-ever half-yearly profit. Revenue is expected to increase by approximately 200% to 230% year-on-year, estimated to be between RMB 527 million and RMB 580 million. The company's key product, the Toumai robot, saw overseas revenue grow by more than 450%, while the overall gross margin improved by over 15 percentage points.

UOB Kay Hian has released a research report stating that MEDBOT-B, founded in 2015, possesses the industry's most comprehensive portfolio of surgical robots, covering applications in laparoscopy, orthopedics, vascular, and urology. Its flagship systems, including Toumai and Skywalker, have already received market approval in China and the European Union. The brokerage firm has initiated coverage on the stock with a 'Buy' rating and a target price of HKD 29.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1149424374?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-11 10:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149424374","market":"nz","top_or_hot":-1,"title":"MEDBOT-B shares surge over 4% intraday; UOB Kay Hian initiates coverage with 'Buy'","media":"Deep News","content":"<p><b>MEDBOT-B</b> (02252) saw its share price rise more than 4% during intraday trading. As of the time of writing, the stock was up 3.25%, trading at HKD 24.12, with a turnover of HKD 59.35 million.<br><br>Recently, <b>MEDBOT-B</b> issued a profit alert, forecasting a net profit of between RMB 28 million and RMB 40 million for the first half of the year. This compares to a loss of RMB 115 million in the same period last year, marking the company's first-ever half-yearly profit. Revenue is expected to increase by approximately 200% to 230% year-on-year, estimated to be between RMB 527 million and RMB 580 million. The company's key product, the Toumai robot, saw overseas revenue grow by more than 450%, while the overall gross margin improved by over 15 percentage points.<br><br>UOB Kay Hian has released a research report stating that <b>MEDBOT-B</b>, founded in 2015, possesses the industry's most comprehensive portfolio of surgical robots, covering applications in laparoscopy, orthopedics, vascular, and urology. Its flagship systems, including Toumai and Skywalker, have already received market approval in China and the European Union. The brokerage firm has initiated coverage on the stock with a 'Buy' rating and a target price of HKD 29.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MEDBOT-B shares surge over 4% intraday; UOB Kay Hian initiates coverage with 'Buy'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMEDBOT-B shares surge over 4% intraday; UOB Kay Hian initiates coverage with 'Buy'\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-08-11 10:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>MEDBOT-B</b> (02252) saw its share price rise more than 4% during intraday trading. As of the time of writing, the stock was up 3.25%, trading at HKD 24.12, with a turnover of HKD 59.35 million.<br><br>Recently, <b>MEDBOT-B</b> issued a profit alert, forecasting a net profit of between RMB 28 million and RMB 40 million for the first half of the year. This compares to a loss of RMB 115 million in the same period last year, marking the company's first-ever half-yearly profit. Revenue is expected to increase by approximately 200% to 230% year-on-year, estimated to be between RMB 527 million and RMB 580 million. The company's key product, the Toumai robot, saw overseas revenue grow by more than 450%, while the overall gross margin improved by over 15 percentage points.<br><br>UOB Kay Hian has released a research report stating that <b>MEDBOT-B</b>, founded in 2015, possesses the industry's most comprehensive portfolio of surgical robots, covering applications in laparoscopy, orthopedics, vascular, and urology. Its flagship systems, including Toumai and Skywalker, have already received market approval in China and the European Union. The brokerage firm has initiated coverage on the stock with a 'Buy' rating and a target price of HKD 29.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1100","symbol_name":"医疗保健设备","start_time":0,"source_url":"","article_id":"1149424374","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149424374","pubTimestamp":1786416634,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"MEDBOT-B (02252) saw its share price rise more than 4% during intraday trading. As of the time of writing, the stock was up 3.25%, trading at HKD 24.12, with a turnover of HKD 59.35 million.Recently,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1100":"医疗保健设备","02252":"微创机器人-B","BK1617":"AI医疗"},"translate_title":"MEDBOT-B 股价盘中飙升超过 4%；大华继显以“买入”开始覆盖","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02252":1},"content_text":"MEDBOT-B (02252) saw its share price rise more than 4% during intraday trading. As of the time of writing, the stock was up 3.25%, trading at HKD 24.12, with a turnover of HKD 59.35 million.Recently, MEDBOT-B issued a profit alert, forecasting a net profit of between RMB 28 million and RMB 40 million for the first half of the year. This compares to a loss of RMB 115 million in the same period last year, marking the company's first-ever half-yearly profit. Revenue is expected to increase by approximately 200% to 230% year-on-year, estimated to be between RMB 527 million and RMB 580 million. The company's key product, the Toumai robot, saw overseas revenue grow by more than 450%, while the overall gross margin improved by over 15 percentage points.UOB Kay Hian has released a research report stating that MEDBOT-B, founded in 2015, possesses the industry's most comprehensive portfolio of surgical robots, covering applications in laparoscopy, orthopedics, vascular, and urology. Its flagship systems, including Toumai and Skywalker, have already received market approval in China and the European Union. The brokerage firm has initiated coverage on the stock with a 'Buy' rating and a target price of HKD 29.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1149424374","isCrawlerRequest":true}